Holen Sie sich die Stockscreener-App
83.29
1.77%
-1.50
Schlusskurs vom Vortag:
$84.79
Offen:
$84.62
24-Stunden-Volumen:
267.24K
Relative Volume:
0.30
Marktkapitalisierung:
$5.21B
Einnahmen:
$209.18M
Nettoeinkommen (Verlust:
$52.04M
KGV:
116.90
EPS:
0.7125
Netto-Cashflow:
$37.10M
1W Leistung:
+1.59%
1M Leistung:
-6.13%
6M Leistung:
+53.70%
1J Leistung:
+120.34%
1-Tages-Spanne:
$82.82
$85.50
1-Wochen-Bereich:
$79.87
$85.50
52-Wochen-Spanne:
$33.70
$96.54
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Firmenname
Protagonist Therapeutics Inc
Sektor
Branche
Telefon
(510) 474-0170
Adresse
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Vergleichen Sie PTGX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
83.36 | 5.30B | 209.18M | 52.04M | 37.10M | 0.7125 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.19 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.79 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
817.04 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
362.61 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.10 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-17 | Eingeleitet | Barclays | Overweight |
| 2025-09-12 | Eingeleitet | Leerink Partners | Outperform |
| 2025-06-17 | Eingeleitet | Citigroup | Buy |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-12-06 | Eingeleitet | Goldman | Neutral |
| 2024-11-05 | Eingeleitet | Wedbush | Outperform |
| 2024-09-24 | Eingeleitet | TD Cowen | Buy |
| 2024-09-09 | Eingeleitet | Truist | Buy |
| 2023-10-30 | Eingeleitet | CapitalOne | Overweight |
| 2023-05-25 | Fortgesetzt | Jefferies | Buy |
| 2022-08-25 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-02-11 | Eingeleitet | BTIG Research | Buy |
| 2021-10-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-10-11 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2021-09-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-05-24 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-05-24 | Eingeleitet | Northland Capital | Outperform |
| 2021-01-06 | Eingeleitet | JP Morgan | Overweight |
| 2020-12-16 | Eingeleitet | Piper Sandler | Overweight |
| 2020-09-18 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-15 | Eingeleitet | Jefferies | Buy |
| 2020-05-18 | Bestätigt | H.C. Wainwright | Buy |
| 2019-07-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-05-09 | Hochstufung | Stifel | Hold → Buy |
| 2018-12-06 | Eingeleitet | Nomura | Buy |
| 2018-01-29 | Eingeleitet | Stifel | Buy |
| 2017-07-21 | Eingeleitet | BTIG Research | Buy |
Alle ansehen
Protagonist Therapeutics Inc Aktie (PTGX) Neueste Nachrichten
Have Insiders Sold Protagonist Therapeutics Shares Recently? - simplywall.st
Protagonist therapeutics CMO Molina sells $784k in shares By Investing.com - Investing.com Canada
Protagonist therapeutics CEO Patel sells $2.84 million in shares By Investing.com - Investing.com India
Asif Ali Sells 8,588 Shares of Protagonist Therapeutics (NASDAQ:PTGX) Stock - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) Insider Arturo Md Molina Sells 9,514 Shares - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells $2,840,446.24 in Stock - MarketBeat
Protagonist therapeutics CEO Patel sells $2.84 million in shares - Investing.com
Protagonist Therapeutics Executives Sell Shares to Cover Tax Obligations - TradingView — Track All Markets
US Market Wrap: Is Protagonist Therapeutics Inc trading at a discount2025 Bull vs Bear & Free Community Consensus Stock Picks - baoquankhu1.vn
Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026 - dailyrecord.com
Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025 - FinancialContent
Earnings Report: Is Protagonist Therapeutics Inc stock good for income investorsQuarterly Investment Review & AI Based Buy and Sell Signals - baoquankhu1.vn
H.C. Wainwright Sticks to Their Buy Rating for Protagonist Therapeutics (PTGX) - The Globe and Mail
Aug Macro: Can Protagonist Therapeutics Inc expand into new marketsM&A Rumor & Weekly Momentum Picks - baoquankhu1.vn
Aug Action: Is BIOX a strong growth stockWeekly Trend Report & Verified Stock Trade Ideas - baoquankhu1.vn
Risk On: Should I add GPUS stock to my portfolio2025 EndofYear Setup & Weekly High Potential Stock Alerts - baoquankhu1.vn
Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis - news-journalonline.com
With Two Partnered Launches Expected In 2026, Protagonist Looks To Next Chapter - Citeline News & Insights
SG Americas Securities LLC Grows Stock Holdings in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Market Fear: Can Protagonist Therapeutics Inc sustain its profitabilityPortfolio Value Summary & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
Trading the Move, Not the Narrative: (PTGX) Edition - Stock Traders Daily
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? - 富途资讯
Day Trade: Can Protagonist Therapeutics Inc expand into new marketsJuly 2025 Sector Moves & Intraday High Probability Setup Alerts - baoquankhu1.vn
Fundamentals Check: Is Protagonist Therapeutics Inc stock a falling knife or bargain buyShare Buyback & Stepwise Trade Signal Implementation - baoquankhu1.vn
Protagonist Therapeutics, Inc Updates on Clinical Developments and Collaborations - TradingView — Track All Markets
Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting - Greenville Online
Is Protagonist Therapeutics Inc. stock overvalued by current metricsWeekly Risk Report & Verified Momentum Watchlists - ulpravda.ru
Is Protagonist Therapeutics Inc. stock a contrarian buy2025 Investor Takeaways & Reliable Entry Point Alerts - Улправда
Protagonist Therapeutics, Inc.Common Stock (NQ: PTGX - FinancialContent
Can Protagonist Therapeutics Inc. stock rebound after recent weaknessWatch List & AI Driven Stock Reports - Улправда
History Review: How Protagonist Therapeutics Inc. stock benefits from strong dollarJuly 2025 Snapshot & Daily Volume Surge Signals - Улправда
Will Protagonist Therapeutics Inc. stock remain a Wall Street favoriteJuly 2025 Chart Watch & Accurate Intraday Trade Tips - Улправда
Is It Too Late To Consider Protagonist Therapeutics (PTGX) After Its 119% One-Year Surge? - Yahoo Finance
Protagonist Therapeutics Advances Pipeline Amid Financial Loss - MSN
Protagonist Therapeutics, Inc. (PTGX) Stock Analysis: Exploring a 14.44% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Protagonist (PTGX) Stock Pre-Market (-6.4%): NDA Submission For Rusfertide Triggers Sell-The-News - Trefis
Protagonist Therapeutics (PTGX) Target Price Raised by Truist Se - GuruFocus
Truist raises Protagonist Therapeutics stock price target to $110 on pivotal year ahead - Investing.com Canada
Stocks Generating Improved Relative Strength: Protagonist Therapeutics - MSN
Citigroup Initiates Coverage of Protagonist Therapeutics (PTGX) with Buy Recommendation - MSN
Protagonist Therapeutics Earnings Notes - Trefis
(PTGX) Volatility Zones as Tactical Triggers - Stock Traders Daily
Moody Aldrich Partners LLC Sells 27,510 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025 - Galesburg Register Mail
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Finanzdaten der Protagonist Therapeutics Inc-Aktie (PTGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Protagonist Therapeutics Inc-Aktie (PTGX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| PATEL DINESH V PH D | President and CEO |
Jan 20 '26 |
Sale |
82.48 |
34,438 |
2,840,446 |
580,505 |
| Ali Asif | Chief Financial Officer |
Jan 20 '26 |
Sale |
82.48 |
8,588 |
708,338 |
78,077 |
3.31%
2.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):